-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, PEhlfE4UphfTTOTrhiwQimvYNyyV1fCTrlHVQJiM8b1zhrN5MrX+Jfjj4xaJehJF gL67ESuwFC7AQ5PROlOPRg== 0001030653-09-000021.txt : 20091005 0001030653-09-000021.hdr.sgml : 20091005 20091005162248 ACCESSION NUMBER: 0001030653-09-000021 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20091001 FILED AS OF DATE: 20091005 DATE AS OF CHANGE: 20091005 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cassidy Sean A CENTRAL INDEX KEY: 0001421914 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-23223 FILM NUMBER: 091105837 MAIL ADDRESS: STREET 1: 322 EAST MAIN STREET CITY: BRANFORD STATE: CT ZIP: 06405 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CURAGEN CORP CENTRAL INDEX KEY: 0001030653 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 061331400 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 322 EAST MAIN STREET CITY: BRANFORD STATE: CT ZIP: 06405 BUSINESS PHONE: 203 481 1104 MAIL ADDRESS: STREET 1: 322 EAST MAIN STREET CITY: BRANFORD STATE: CT ZIP: 06405 4 1 edgar.xml PRIMARY DOCUMENT X0303 4 2009-10-01 1 0001030653 CURAGEN CORP CRGN 0001421914 Cassidy Sean A 322 EAST MAIN STREET BRANFORD CT 06405 0 1 0 0 Former VP & CFO Common Stock 2009-10-01 4 D 0 50000 D 0 D Stock Option Right to Buy .69 2009-10-01 4 D 0 50000 D 2010-10-01 Common Stock 50000 0 D Stock Option Right to Buy .68 2009-10-01 4 D 0 159600 D 2010-10-01 Common Stock 159600 0 D Disposed of pursuant to merger agreement between issuer and Celldex Therapeutics, Inc. in exchange for 13,695 shares of Celldex Therapeutics, Inc. common stock having a market value of $19.82 per share on the effective date of the merger, October 1, 2009. This option vested 25% on January 24, 2009 and 6.25% quarterly thereafter until the effective date of the merger at which time the option was accelerated and assumed by Celldex Therapeutics, Inc. and replaced with an option to purchase 13,695 shares of Celldex Therapeutics, Inc. common stock for $2.52 per share. This option, which accelerated on October 1, 2009, was assumed by Celldex Therapeutics, Inc. in the merger and replaced with an option to purchase 43,714 shares of Celldex Therapeutics, Inc. common stock for $2.48 per share. Sean A. Cassidy 2009-10-05 -----END PRIVACY-ENHANCED MESSAGE-----